SAN FRANCISCO, July 28, Jul 28, 2021 (GLOBE NEWSWIRE via COMTEX) --
SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.
("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 41
Annual Growth Conference, being held virtually on Wednesday, August 11, 2021 at 3:00 p.m. ET (12:00 p.m. PT).
A live webcast of the presentation may be accessed under the Investors & Media section of Olema's website ( www.olema.com ) and will be archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Vice President, Communications and Investor Relations
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.
(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.